Overview

* AbbVie Q3 2025 rev grows 9.1%, beating analyst expectations

* Adjusted EPS for Q3 beats consensus, despite $1.50/share IPR&D impact

* Company raises 2025 adjusted EPS guidance, announces 5.5% dividend increase for 2026

Outlook

* AbbVie ( ABBV ) raises 2025 adjusted EPS guidance to $10.61 - $10.65

* Company announces 5.5% dividend increase for 2026

Result Drivers

* IMMUNOLOGY GROWTH - Strong performance in immunology portfolio with Skyrizi and Rinvoq driving revenue increases

* NEUROSCIENCE PERFORMANCE - Neuroscience portfolio saw a 20.2% revenue increase, driven by Vraylar and Botox Therapeutic

* ONCOLOGY DECLINE - Oncology portfolio revenues decreased slightly, with Imbruvica seeing a 14.8% decline

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $15.78 $15.59

Revenue bln bln (19

Analysts

)

Q3 Beat $1.86 $1.77

Adjusted (16

EPS Analysts

)

Q3 EPS $0.10

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for AbbVie Inc ( ABBV ) is $242.50, about 5.9% above its October 30 closing price of $228.20

* The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 14 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)